The BeVigilant™ OraFusion™ System

The BeVigilant™ OraFusion™ System provides a simple, accurate, and chairside method for the early detection of oral cancer.

Using a saliva-based lateral flow immunoassay and the BeVigilant™ Reader, it identifies the presence of biomarkers associated with oral cancer and integrates them with clinical risk factors to deliver an objective, real-time risk assessment.
In just 15 minutes or less, practitioners can determine whether a patient should be monitored or investigated further - empowering earlier intervention and better outcomes.
Why OraFusion™?
• The first and only real-time early oral cancer detection system
• Combines two salivary biomarkers with patient risk factors for enhanced diagnostic accuracy
• Provides objective, reproducible results at the point of care
• Non-invasive and comfortable for patients
• Enables timely specialist referral and treatment planning

Clinical Context
• Oral Potentially Malignant Disorders (OPMDs) account for up to 80% of oral cancer cases
• 29% of dental patients present with an oral abnormality during a routine visit
• 72% of oral cancer cases are diagnosed late (Stage III or IV), leading to poorer prognosis
• The overall malignant transformation rate of OPMDs is 7.9%
• Objective, in-chair testing supports earlier detection and improved survival rates